

Declining Trend of Sudden Cardiac Death in Younger Individuals: A 20–Year Nationwide Study

Running title: 20-year Temporal Trends in Young SCD

Authors

Carl Johann Hansen MD^{a,b}, Jesper Svane MD PhD^{a,b}, Peder Emil Warming MD^a, Thomas Hadberg Lyngø MD PhD^a, Rodrigue Garcia MD PhD^{a,c,d}, Carolina Malta Hansen MD PhD^{e,f,g}, Christian Torp-Pedersen MD DMSc^{h,i}, Jytte Banner MD PhD^b, Bo Gregers Winkel MD PhD^{a,*}, Jacob Tfelt-Hansen MD DMSc^{a,b,*}

*Authors contributed equally

Affiliations

^aDepartment of Cardiology, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

^bDepartment of Forensic Medicine, Frederik Vs Vej 11, 2100 Copenhagen University, Denmark

^cUniversity Hospital of Poitiers. Cardiology Department, 2 rue de la Milétrie, 86021 Poitiers, France

^dCentre d'Investigation Clinique 1402. CHU de Poitiers, 2 rue de la Milétrie, 86021 Poitiers, France

^eCopenhagen Emergency Medical Services, Telegrafvej 5, 2750 Ballerup, Denmark

^fHerlev and Gentofte Hospital, Department of Cardiology, Gentofte Hospitalsvej 1, 2900 Hellerup, Denmark

^gDepartment of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2100 Copenhagen, Denmark

^hDepartment of Cardiology, Nordsjællands Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark

ⁱDepartment of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1353 Copenhagen, Denmark

Corresponding author:

Carl Johann Hansen, MD. Department of Cardiology, Copenhagen University Hospital – Rigshospitalet, 2142, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Tel: (+45) 61 71 53 00. Email: carl.johann.hansen@regionh.dk

Word count: 7452

Abstract

Background

Declining all-cause and cardiovascular mortality rates have been well-documented, yet temporal trends of sudden cardiac death (SCD) in the young are unclear. We provide contemporary nationwide estimates of the incidence and temporal trends of SCD in the young aged 1–35 from 2000–2019 and evaluate these trends in relation to changes in out-of-hospital cardiac arrest (OHCA) patterns and implantable cardioverter defibrillator (ICD) implantations.

Method

All individuals aged 1–35 living in Denmark from 2000–2019 were included. Adjudication of SCD cases relied on multiple sources, including death certificates, medical files, and autopsy reports. All OHCA were captured in a nationwide prospective registry, and ICD implantations were registered through administrative registries. Crude and sex- and age-standardized annual incidence rates of SCD were calculated, and temporal changes in SCD incidence were computed as percentage change annualized (PCA). Trends in OHCA survival and characteristics, as well as ICD implantations, were assessed.

Results

During the 20-year study period (47.5 million person-years), 1 057 SCD were identified (median age 29 years, 69% male sex). The overall incidence of SCD was 2.2 per 100 000

person-years and declined by 3.31% (95%CI 2.42 to 4.20) annually, corresponding to a 49.0% (95%CI 38.7 to 57.6) reduction during the study. Rates of witnessed SCD declined markedly (PCA -7.03% [95%CI -8.57 to -5.48]), but we observed no changes in the rate of unwitnessed SCD (PCA -0.09% [95%CI -1.48 to 1.31]). Consequently, the proportion of unwitnessed SCD increased by 79% ($p<0.001$). Survival after OHCA in young individuals aged 1–35 increased from 3.9% to 28% in the same time frame, mainly attributable to increased bystander CPR and defibrillation. The implantation rate of ICD increased from 0.76 to 1.55 per 100 000 PY, and the prevalence of young individuals with an ICD increased 16-fold.

Conclusion

SCD incidence rates in the young declined by 49% over the last two decades. The decline was paralleled by improved survival in OHCA victims and higher ICD implantation rates. However, rates of unwitnessed SCD were unchanged, which calls for new perspectives in preventive strategies.

Keywords

Sudden cardiac death, epidemiology, temporal trends, prevention, resuscitation, cardiac arrest

74 Clinical Perspectives

75 What is new? (max 100 words, 2-3 bullets)

- 76 • Over the past 20 years, the incidence of SCD in young individuals aged 1–35
77 declined by 49%.
- 78 • Concomitantly, the 30-day survival after OHCA increased from 4% to 28%,
79 driven by improved bystander CPR rates reaching +80%, and ICD implantations
80 in young adults increased markedly.
- 81 • We observed no decline in the incidence of unwitnessed SCD during the study
82 period.

83 What are the clinical implications (max 100 words, 2-3 bullets)

- 84 • As the majority (73%) of SCD in the most recent years were unwitnessed,
85 preventive strategies targeting unwitnessed cardiac arrests need further
86 attention. Incorporating connected devices, e.g. smart watches, in prevention
87 could potentially help identify ventricular arrhythmias and thus improve
88 survival among unwitnessed cardiac arrest.
- 89 • Low bystander AED rates (8%) call for further improvement in early AED
90 deployment.

91

92 Non-standard Abbreviations and Acronyms

93 CA = Cardiac arrest

94 ICD = Implantable cardioverter-defibrillator

95 IR = Incidence Rate

96 IRR = Incidence Rate Ratio

97 OHCA = Out-of-hospital cardiac arrest

98 SCD = Sudden Cardiac Death

99

Introduction

While overall and cardiovascular disease mortality rates in Western countries have declined in recent decades^{1,2}, sudden cardiac death (SCD) among young individuals aged ≤ 35 years continues to pose a significant public health challenge associated with vast psychological consequences and a substantial loss of productive years^{3,4}.

Previous studies have shown that the incidence rates (IR) of SCD among young individuals range from 1–3 per 100 000 person-years^{5,6}, yet there is limited research on contemporary data, and previous studies on temporal trends have been conflicting^{7–11}.

As the causes and circumstances of cardiac arrest are strongly age-dependent¹², temporal trends in the elderly population cannot reliably be extrapolated to the young.

Given the decline in mortality rates over the past decades, contemporary estimates of SCD incidence are crucial for evaluating and implementing specific preventive health initiatives targeting the young.

In the current study, we aimed to provide contemporary estimates of the incidence of SCD in the young aged 1–35 years and evaluate the temporal trends from 2000–2019 in relation to changes in out-of-hospital cardiac arrest (OHCA) patterns and implantable cardioverter defibrillator (ICD) implantations. Furthermore, we aimed to identify subgroups of the SCD population, in which current preventive strategies have had less impact and where targeted preventive initiatives could be beneficial.

Methods

This nationwide observational study complies with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for observational studies.

Data availability

Data are owned by a third party, and the authors do not have the right to share data; however, upon request, the authors will help in applying to the third party for approval of data sharing.

Data sources

All Danish citizens are assigned a unique civil registration number, which allows data linkage at the individual level across the administrative registries in Denmark. These registers are government-maintained and comprise longitudinally collected administrative and health-care data¹³.

Information from the following registries was included: *The Danish Civil Registration System* holds information on sex, migration, and vital status and was used to identify the study population¹³. *The Danish Register of Causes of Death* holds information on the causes and circumstances of all deaths in Denmark¹⁴. *The National Patient Registry* holds information on all hospital encounters and procedures (in-patient since 1978 and out-patient since 1995) and was used to identify comorbidities and ICD implantations¹⁵. *The Danish National Prescription Registry* holds information on

prescriptions redeemed at Danish pharmacies since 1995 and was used to identify comorbidities and comedication¹⁶.

Additional data sources were a clinical database containing detailed information on all young SCD aged 1–35 in Denmark from 2000–2019⁶, and the *Danish Cardiac Arrest Registry*, which comprises information on all out-of-hospital cardiac arrests (OHCA) in Denmark since 2001 with attempted resuscitation by emergency medical services¹⁷.

Study population and characteristics

All individuals aged 1–35 years living in Denmark during 2000–2019 were included. The annual at-risk population was identified on 1 January of each year (index date).

SCD cases were identified through a multi-source approach, which has previously been described in detail^{6,18}. Adjudication was based on manual examination of all death certificates, autopsy reports, and discharge summaries preceding death during the study period. SCD was defined as the *sudden, unexpected death of presumed cardiac origin that occurs within 1 hour of symptom onset in witnessed cases and within 24 hours of last seen alive and well in unwitnessed cases*¹⁹.

To contextualize the trends in SCD, we examined trends in 1) survival and bystander interventions in all OHCA aged 1–35 registered in the Danish Cardiac Arrest Registry from 2001–2019 and 2) all ICD implantations registered during the study period in individuals aged 1–35. ICD implantations were identified by procedural codes from the National Patient Registry (ICD-10 code: BFCB0) and subsequently categorized as either

primary prophylactic (no previous record of a cardiac arrest) or secondary prophylactic (in patients with a previous cardiac arrest).

Comorbidities were identified from the *Danish National Patient Registry* as any hospital contact with a given diagnosis in the ten years preceding the index date; additionally, hypertension, diabetes, and psychiatric disease were identified by recent co-medication^{20,21}. Any comorbidity was defined as the presence of hypertension, cardiovascular disease (CVD), chronic kidney disease (CKD), diabetes, COPD, epilepsy, and psychiatric disease (see *Suppl. Table 1* for definitions of comorbidity). Information on comorbidities was available until 2018.

Statistical analyses

The study period was divided into 4-year intervals (2000-2003, 2004-2007, 2008-2011, 2012-2015, and 2016-2019) to compare characteristics over time. For descriptive statistics, categorical variables were presented as count and percentages and continuous variables as median and interquartile range (IQR). Temporal trends in continuous variables were assessed with linear regression and presented as 20-year absolute change, and in categorical variables with logistic regression with year as a covariate and presented as 20-year relative risk.

IR were calculated as the ratio between mortality counts and the appropriate background population with confidence intervals calculated by Poisson's exact method. Annual IR were standardized on age and sex by direct standardization, using 5-year age

groups and the average Danish population throughout the study period as the standard population. Confidence intervals for directly standardized incidence rates (DSIR) were calculated based on the gamma distribution²². Temporal trends in DSIR were calculated as the percentage change annualized (PCA) by fitting log-linear models to the DSIR, using weighted least square regression²³. PCA values were compared by a Wald test of the log-linear models.

A two-sided p-value of 5% was considered significant. All calculations were performed in R v. 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria) using the following packages: *data.table*, *targets*, *tidyverse*, *heaven*, and *gtsummary*.

Ethics

This study complies with the Helsinki Declaration and was approved by the Regional Data Committee (P-2019-813 and P-2019-523). Registry-based studies on deidentified data are exempt from ethical approvals in Denmark. Due to data regulations, counts below four have been masked (≤ 3) throughout the manuscript.

Results

During the 20-year study period, 4 274 630 unique individuals were observed for 47.5 million person-years (PY). In total, 15 186 deaths occurred, of which 1 057 (7%) were categorized as SCD.

Trends in population characteristics

The average population in Denmark aged 1–35 was 2.38 mill (median age: 18 years [IQR 10–27], 51% male), and both population size, age, and sex distribution remained stable throughout the study (*Suppl. Table 2*). While the overall comorbidity burden was low, the prevalence of most comorbidities increased annually. Notably, the prevalence of individuals with a previous cardiac arrest or an ICD increased significantly during the study period (estimated 20-year RR: 8.05 ($p < 0.001$) and 11.03 ($p < 0.001$), respectively).

Clinical characteristics of the 1 057 SCD (median age: 29 [IQR 22–33], 69% male) stratified by time period are shown in *Table 1*. Throughout the study period, there was a trend towards a higher proportion of male sex (estimated 20-year RR: 1.13, $p = 0.085$). The prevalence of CVD remained constant (15%, p for trend = 0.55). The autopsy rate was stable at 67% (p for trend 0.64), and no substantial changes in causes of death were observed. The proportion of unwitnessed SCD increased by 79% during the study period (estimated 20-year RR: 1.79, $p < 0.001$).

SCD Incidence rates and temporal trends

SCD Incidence rates are presented in *Table 2*. The overall SCD IR throughout the entire study period was 2.2 per 100 000 PY (95%CI 2.1–2.4). Crude SCD rates decreased from 2.89 per 100 000 PY (95%CI 2.56–3.24) in 2000–2003 to 1.67 (95%CI 1.42–1.94) per 100 000 PY in 2016–2019. After sex- and age adjustment, the annual decline (percentage change annualized [PCA]) was -3.31% (95%CI -4.20; -2.42), accumulating to

218 a 49.0% (95%CI 38.7–57.6) reduction in the SCD incidence over the 20-year period
219 (*Figure 1*).

220 We observed marked differences in SCD incidence according to sex and witnessed
221 status. Males were at considerably higher risk of SCD (IRR: 2.2 [95%CI 1.9–2.5,
222 $p < 0.001$]), and there was a trend towards an increasing discrepancy between the sexes
223 throughout the study period, illustrated by a 1.9% lower PCA in males compared to
224 females (p for difference = 0.052) (*Figure 2A*). The incidence of witnessed SCD
225 decreased significantly with a PCA of -7.03% (95%CI -8.57; -5.48). Contrarily, we
226 observed no difference in the incidence of unwitnessed SCD (PCA -0.09% [95%CI –
227 1.48;1.31])(*Figure 2B*).

228 Out-of-hospital cardiac arrest

229 From 2001–2019, 2 256 OHCA in individuals aged 1–35 years were registered (median
230 age 25 [IQR 19–31], 70% male sex). Comparing the first and the last time periods, we
231 observed increasing proportions of witnessed OHCA (28% to 39%, $p < 0.001$), bystander
232 cardiopulmonary resuscitation (CPR) (30% to 79%, $p < 0.001$), bystander defibrillation
233 (1.8% to 7.7%, $p < 0.001$) and 30-day survival (3.9% to 28%, $p < 0.001$) (*Figure 3*). Overall,
234 OHCA characteristics were similar between both sexes except for females being
235 younger (24 vs 26 years, $p = 0.014$) and OHCA in women more often occurring in
236 private residences (67% vs 56%, $p < 0.001$). 30-day survival was significantly better
237 among females (22% vs 16%, $p < 0.001$). When temporal changes in OHCA

characteristics were assessed, bystander CPR and defibrillation rates improved markedly more among women and surpassed the rates among males (*Suppl Table 3*).

ICD implantation

During the 20-year study period, 606 ICDs (406 primary prevention, 200 secondary prevention) were implanted in individuals aged 1–35 years (*Figure 4*). The ICD-implantation rate doubled from 73 implantations in 2000-2003 (IR 0.76 per 100 000 PY) to 150 in 2016-2019 (IR 1.55 per 100 000 PY), and the proportion of secondary preventive ICDs increased from 19% to 38%.

Discussion

This longitudinal, study provides contemporary nationwide incidence estimates for SCD based on a large cohort of young SCD cases aged 1–35 years in Denmark. The study's principal findings include a significant decrease in the incidence of SCD (49% over the last 20 years), a substantially 7-fold improved survival following OHCA in young individuals and higher rates of ICD implantation. We believe this is among the first studies to contextualize the trends in SCD to OHCA survival and ICD implantations in young individuals. Notably, the study provides an up-to-date overview of the epidemiology of SCD with potential implications for future preventive initiatives to reduce SCD.

Incidence rates of SCD

The reported IR of 1.67 per 100 000 PY in the most recent time period (2016–2019) is comparable to the IR reported in the literature^{5,10,24,25}. Direct cross-study comparison of incidence rates is difficult due to vast differences in methodology and study populations. Our multi-source identification of SCD, based on all deaths in Denmark from 2000–2019, reduces the risk of selection bias typically associated with epidemiological studies on selected populations (autopsy cohorts) or ICD-codes from death certificates, and we believe it offers the most accurate estimate of the true burden of SCD.

More importantly, we observed a 3.3% annual decline in SCD incidence, accumulating to a 49% reduction in SCD over the 20-year study period. All observed subgroups exhibited declining rates, apart from unwitnessed SCD, where the IR remained stable. Our group has previously reported temporal trends in young SCD from 2000–2009⁹, and the trend has continued to decline at a comparable rate over the past decade. Similar findings have been reported in young SCD^{7,26}, SCD in all ages^{2,11}, and cardiovascular mortality², supporting an overall trend of declining SCD mortality.

Improved survival after OHCA

The reduction in SCD mortality is multifactorial, but improved survival after OHCA is among the most important contributors. Several strategies to improve OHCA survival have been implemented in Denmark in the last decades, including widespread CPR

277 training, lay-person activation ("Heart runner" program), and increased public
 278 automated external defibrillators (AED) availability^{27,28}, and the effects of these
 279 community-based interventions on survival are well documented^{29,30}. During the study
 280 period, survival after OHCA in individuals aged 1–35 increased from 4% to 28%,
 281 concomitantly with an increase in bystander CPR and defibrillation to approximately
 282 80% and 8%, respectively. Although a significant proportion of OHCA in young
 283 individuals are non-cardiac³¹, this improved survival translates directly into a lower SCD
 284 incidence. Although the rate of bystander defibrillation increased significantly during
 285 the study period, AEDs were only used in 8% of the young OHCA victims. The low rate
 286 was likely due to most arrests occurring in private homes, where rates of bystander
 287 defibrillation remain low¹⁷. Early bystander defibrillation is a key prognostic factor for
 288 survival²⁹, and further improvement in the rate of bystander AED use is critical in
 289 improving survival.

290 The proportion of female SCD decreased during the study period, although just missing
 291 statistical significance ($p = 0.058$) – we think this is likely an issue of statistical power.
 292 Similar findings have been described in studies of both younger¹⁰ and older¹¹ SCD
 293 cohorts, and higher OHCA survival rates have been reported in females^{32,33}. In the
 294 current study, bystander CPR and defibrillation rates — key prognostic markers for
 295 improved survival — increased among both sexes, but the increase was markedly
 296 higher among women, where the rates even surpassed those among males. This
 297 difference likely contributed to the observed discrepancy between sexes in OHCA

survival and SCD incidence. The equal CPR and defibrillation rates in recent years contrast previous reports of OHCA in females^{33,34} and could reflect differences in study populations and characteristics (younger age in the current study) or cultural differences towards resuscitation attempts in younger women.

Prevention of SCD and identification of high-risk individuals

ICD implantation is a key component in preventing SCD in high-risk patients, as it significantly reduces the risk of arrhythmic death^{19,35}. During the study period, the prevalence of ICDs in the young general population increased more than 10-fold, which is likely multifactorial. First, as the number of OHCA survivors increases, more patients will be eligible for ICD implantation. Causes of OHCA among young individuals differ from the elderly with more structural and inherited cardiac disease^{12,18}, in whom secondary ICD implantation is more likely. Accordingly, we observed an increased ICD implantation in cardiac arrest survivors. Similar findings have been reported in Western Australia, where ICD implantation rates increased 15-fold from 1995 to 2009¹¹, paralleled by improved OHCA survival. Second, substantial improvements in our understanding of the pathophysiology and genetics underlying inherited cardiac diseases have improved risk stratification significantly. Combined with systematic family cascade screening of relatives to SCA/SCD victims, in whom the risk of inherited cardiac diseases is significantly higher³⁶, we likely identify more individuals at risk of SCD who are eligible for a primary preventive ICD.

318 For both primary and secondary prevention ICDs, whether mortality reduction is due to
319 the actual ICD, improved medical care and awareness in patients with an ICD
320 (performance bias), or a combination remains speculative. However, a recent study by
321 Ruwald et al.²⁸ found a significant decline in the delivery of appropriate shocks in
322 patients with secondary ICDs during the last decade, and thus fewer who seem to
323 benefit from their ICD. As young individuals with an ICD have a high lifetime risk of
324 device-related complications³⁷, this finding highlights the need for better pre-
325 implantation risk stratification and identification of those who may benefit from an ICD,
326 in order to reduce unnecessary implantations.

327 A surprising finding of this study was the discrepancy in SCD trends between witnessed
328 and unwitnessed SCD. As we only observed declining rates of SCD that were witnessed,
329 the proportion of unwitnessed SCD increased by 79% to approximately three in four,
330 which is markedly higher than previously reported^{38,39}. Previous studies have identified
331 key differences between witnessed and unwitnessed SCD — e.g. more unexplained
332 deaths, higher proportion of males, different comorbidity profiles and more frequent
333 death during sleep among unwitnessed SCD^{38,40}. Therefore, this shift has substantial
334 implications for the epidemiology of SCD, and future preventive measures must reflect
335 this change as strategies targeting OHCA may have a limited impact on preventing
336 unwitnessed SCD. Prevention of SCD that occur unwitnessed or during sleep is
337 particularly difficult, as timely recognition and intervention is hindered and survival
338 chances thus dramatically lower. However, connected devices —e.g., smart watches

and speakers— are increasingly capable of identifying malignant arrhythmias and alerting first responders or family members^{41,42}. Although these solutions are still in their infancy, they present an exciting opportunity to monitor high-risk patients and lower mortality^{43,44}.

Study limitations

We acknowledge several limitations of our study. First, the observational nature imposes limitations on the assertions of causality, and interpretation should be made with caution. Second, changes in coding practices, diagnostic criteria, and procedural indications during the 20-year study period may have impacted the observed trends. However, this would primarily affect estimates of comorbidity and have less impact on SCD rates due to the multi-source identification of SCD. Similarly, the OHCA registry has undergone administrative changes during the study period with improved capture due to electronic registration since 2016. However, the improving trend in survival was observed throughout the entire study period, indicating that the underreporting of OHCA cases was likely at random with little effect on our estimates. We had no information about ICD therapies, which could have added further insight into the value if increased ICD implantation. Last, information on modifiable risk factors (BMI, smoking, alcohol intake, activity level) that may influence disease patterns was not available from the national registries.

Conclusion

Over the past 20 years, there has been a 49% decrease in the incidence of SCD in young individuals aged 1–35 in Denmark. Steep inclines in both ICD implantations and survival rates of cardiac arrest victims paralleled the decline. However, we observed no change in the incidence of unwitnessed SCD, and preventive efforts need to address this issue, e.g., by concentrating on near-term prevention.

Acknowledgements

The authors acknowledge the Danish Clinical Quality Program – National Clinical Registries (RKKP). for making it possible to work with data from the Danish Cardiac Arrest Registry.

Sources of funding

This study was supported by an internal grant from the University of Copenhagen, Denmark. However, the university did not influence the study design, data acquisition, data analysis, or article preparation or any effect on the publication process.

376 Disclosures

377 The other authors report no conflicts of interest.

378

379 Supplemental Material

380 Tables S1–S3

References

1. Wang H, Abbas KM, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2020;396:1160–1203. doi:10.1016/S0140-6736(20)30977-6.
2. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. *Circulation* 2004;110:522–527. doi:10.1161/01.CIR.0000136993.34344.41.
3. Empana J-P, Lerner I, Valentin E, Folke F, Böttiger B, Gislason G, et al. Incidence of Sudden Cardiac Death in the European Union. *Journal of the American College of Cardiology* 2022;79:1818–1827. doi:10.1016/j.jacc.2022.02.041.
4. Waldmann V, Karam N, Bougouin W, Sharifzadehgan A, Dumas F, Narayanan K, et al. Burden of Coronary Artery Disease as a Cause of Sudden Cardiac Arrest in the Young. *Journal of the American College of Cardiology* 2019;73:2118–2120. doi:10.1016/j.jacc.2019.01.064.
5. Couper K, Putt O, Field R, Poole K, Bradlow W, Clarke A, et al. Incidence of sudden cardiac death in the young: a systematic review. *BMJ Open* 2020;10:e040815. doi:10.1136/bmjopen-2020-040815.
6. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al. Nationwide study of sudden cardiac death in persons aged 1–35 years. *European Heart Journal* 2011;32:983–990. doi:10.1093/eurheartj/ehq428.
7. Vähätalo J, Holmström L, Pakanen L, Kaikkonen K, Perkiömäki J, Huikuri H, et al. Temporal Trends in the Incidence and Characteristics of Sudden Cardiac Death among Subjects under 40 Years of Age in Northern Finland during 1998–2017. *Cardiology* 2022;147:328–331. doi:10.1159/000522554.
8. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in Sudden Cardiovascular Death in Young Competitive Athletes After Implementation of a Preparticipation Screening Program n.d.
9. Lynge TH, Nielsen JL, Blanche P, Gislason G, Torp-Pedersen C, Winkel BG, et al. Decline in incidence of sudden cardiac death in the young: a 10-year nationwide study of 8756 deaths in Denmark. *EP Europace* 2019;21:909–917. doi:10.1093/europace/euz022.
10. Wisten A, Krantz P, Stattin E-L. Sudden cardiac death among the young in Sweden from 2000 to 2010: an autopsy-based study. *Europace* 2016;euw249. doi:10.1093/europace/euw249.
11. Feng J-L, Nedkoff L, Knuiman M, Semsarian C, Ingles J, Briffa T, et al. Temporal Trends in Sudden Cardiac Death From 1997 to 2010: A Data Linkage Study. *Heart, Lung and Circulation* 2017;26:808–816. doi:10.1016/j.hlc.2016.11.021.

- 417 12. Lynge TH, Nielsen JL, Risgaard B, Werf C van der, Winkel BG, Tfelt-Hansen J. Causes of sudden
418 cardiac death according to age and sex in persons aged 1–49 years. *Heart Rhythm* 2023;20:61–
419 68. doi:10.1016/j.hrthm.2022.08.036.
- 420 13. Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, et al. The Danish
421 health care system and epidemiological research: from health care contacts to database
422 records. *CLEP* 2019;Volume 11:563–591. doi:10.2147/CLEP.S179083.
- 423 14. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand J Public Health* 2011;39:26–29.
424 doi:10.1177/1403494811399958.
- 425 15. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish
426 National Patient Registry: a review of content, data quality, and research potential. *Clin*
427 *Epidemiol* 2015;7:449–490. doi:10.2147/CLEP.S91125.
- 428 16. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data
429 Resource Profile: The Danish National Prescription Registry. *International Journal of*
430 *Epidemiology* 2017;46:798–798f. doi:10.1093/ije/dyw213.
- 431 17. Danish Cardiac Arrest Registry. Danish Cardiac Arrest Registry: Executive Summary of the
432 Annual Report 2022. n.d.
- 433 18. Lynge TH, Risgaard B, Banner J, Nielsen JL, Jespersen T, Stampe NK, et al. Nationwide burden of
434 sudden cardiac death: A study of 54,028 deaths in Denmark. *Heart Rhythm* 2021.
435 doi:10.1016/j.hrthm.2021.05.005.
- 436 19. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC
437 Guidelines for the management of patients with ventricular arrhythmias and the prevention of
438 sudden cardiac death: Developed by the task force for the management of patients with
439 ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of
440 Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital
441 Cardiology (AEPC). *European Heart Journal* 2022;43:3997–4126.
442 doi:10.1093/eurheartj/ehac262.
- 443 20. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk
444 stratification schemes for predicting stroke and thromboembolism in patients with atrial
445 fibrillation: nationwide cohort study. *BMJ* 2011;342:d124. doi:10.1136/bmj.d124.
- 446 21. Lynge TH, Svane J, Pedersen-Bjergaard U, Gislason G, Torp-Pedersen C, Banner J, et al. Sudden
447 cardiac death among persons with diabetes aged 1–49 years: a 10-year nationwide study of 14
448 294 deaths in Denmark. *European Heart Journal* 2020;41:2699–2706.
449 doi:10.1093/eurheartj/ehz891.
- 450 22. Fay MP, Feuer EJ. CONFIDENCE INTERVALS FOR DIRECTLY STANDARDIZED RATES: A METHOD
451 BASED ON THE GAMMA DISTRIBUTION. *Statist Med* 1997;16:791–801. doi:10.1002/(SICI)1097-
452 0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#.

- 453 23. Fay MP, Tiwari RC, Feuer EJ, Zou Z. Estimating Average Annual Percent Change for Disease Rates
454 without Assuming Constant Change. *Biometrics* 2006;62:847–854. doi:10.1111/j.1541-
455 0420.2006.00528.x.
- 456 24. Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L, et al. A Prospective Study of
457 Sudden Cardiac Death among Children and Young Adults. *N Engl J Med* 2016;374:2441–2452.
458 doi:10.1056/NEJMoa1510687.
- 459 25. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, et al. Current burden of sudden
460 cardiac death: Multiple source surveillance versus retrospective death certificate-based review
461 in a large U.S. community. *Journal of the American College of Cardiology* 2004;44:1268–1275.
462 doi:10.1016/j.jacc.2004.06.029.
- 463 26. Ha FJ, Han H-C, Sanders P, Fendel K, Teh AW, Kalman JM, et al. Sudden Cardiac Death in the
464 Young. *Circulation: Cardiovascular Quality and Outcomes* 2020;13:e006470.
465 doi:10.1161/CIRCOUTCOMES.119.006470.
- 466 27. Wissenberg M, Lippert FK, Folke F, Weeke P, Hansen CM, Christensen EF, et al. Association of
467 National Initiatives to Improve Cardiac Arrest Management With Rates of Bystander
468 Intervention and Patient Survival After Out-of-Hospital Cardiac Arrest. *JAMA* 2013;310:1377–
469 1384. doi:10.1001/jama.2013.278483.
- 470 28. Hansen CM, Lippert FK, Wissenberg M, Weeke P, Zinckernagel L, Ruwald MH, et al. Temporal
471 trends in coverage of historical cardiac arrests using a volunteer-based network of automated
472 external defibrillators accessible to laypersons and emergency dispatch centers. *Circulation*
473 2014;130:1859–1867. doi:10.1161/CIRCULATIONAHA.114.008850.
- 474 29. Kragholm K, Wissenberg M, Mortensen RN, Hansen SM, Malta Hansen C, Thorsteinsson K, et al.
475 Bystander Efforts and 1-Year Outcomes in Out-of-Hospital Cardiac Arrest. *N Engl J Med*
476 2017;376:1737–1747. doi:10.1056/NEJMoa1601891.
- 477 30. Simmons KM, Mclsaac SM, Ohle R. Impact of community-based interventions on out-of-hospital
478 cardiac arrest outcomes: a systematic review and meta-analysis. *Scientific Reports* 2023;13.
479 doi:10.1038/s41598-023-35735-y.
- 480 31. Paratz ED, van Heusden A, Zentner D, Morgan N, Smith K, Thompson T, et al. Causes,
481 circumstances, and potential preventability of cardiac arrest in the young: insights from a state-
482 wide clinical and forensic registry. *EP Europace* 2022;24:1933–1941.
483 doi:10.1093/europace/euac141.
- 484 32. Kitamura T, Iwami T, Nichol G, Nishiuchi T, Hayashi Y, Nishiyama C, et al. Reduction in incidence
485 and fatality of out-of-hospital cardiac arrest in females of the reproductive age. *European Heart*
486 *Journal* 2010;31:1365–1372. doi:10.1093/eurheartj/ehq059.
- 487 33. Bougouin W, Mustafic H, Marijon E, Murad MH, Dumas F, Barbouttis A, et al. Gender and
488 survival after sudden cardiac arrest: A systematic review and meta-analysis. *Resuscitation*
489 2015;94:55–60. doi:10.1016/j.resuscitation.2015.06.018.

- 490 34. Blom MT, Oving I, Berdowski J, van Valkengoed IGM, Bardai A, Tan HL. Women have lower
491 chances than men to be resuscitated and survive out-of-hospital cardiac arrest. *European Heart*
492 *Journal* 2019;40:3824–3834. doi:10.1093/eurheartj/ehz297.
- 493 35. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck K-H, Zipes DP, et al. Meta-analysis of the
494 implantable cardioverter defibrillator secondary prevention trials. *European Heart Journal*
495 2000;21:2071–2078. doi:10.1053/euhj.2000.2476.
- 496 36. Ranthe MF, Winkel BG, Andersen EW, Risgaard B, Wohlfahrt J, Bundgaard H, et al. Risk of
497 cardiovascular disease in family members of young sudden cardiac death victims. *European*
498 *Heart Journal* 2013;34:503–511. doi:10.1093/eurheartj/ehs350.
- 499 37. Olde Nordkamp LRA, Wilde AAM, Tijssen JGP, Knops RE, van Dessel PFHM, de Groot JR. The ICD
500 for Primary Prevention in Patients With Inherited Cardiac Diseases. *Circulation: Arrhythmia and*
501 *Electrophysiology* 2013;6:91–100. doi:10.1161/CIRCEP.112.975268.
- 502 38. Svane J, Lynge TH, Hansen CJ, Risgaard B, Winkel BG, Tfelt-Hansen J. Witnessed and
503 unwitnessed sudden cardiac death: a nationwide study of persons aged 1–35 years. *EP*
504 *Europace* 2021;23:898–906. doi:10.1093/europace/euab017.
- 505 39. Jayaraman R, Reinier K, Nair S, Aro AL, Uy-Evanado A, Rusinaru C, et al. Risk Factors of Sudden
506 Cardiac Death in the Young. *Circulation* 2018;137:1561–1570.
507 doi:10.1161/CIRCULATIONAHA.117.031262.
- 508 40. Hansen CJ, Svane J, Lynge TH, Stampe NK, Bhardwaj P, Torp-Pedersen C, et al. Differences
509 among young unwitnessed sudden cardiac death, according to time from last seen alive:
510 Insights from a 15-year nationwide study. *Heart Rhythm* 2023;1504–1509.
511 doi:10.1016/j.hrthm.2023.07.005.
- 512 41. Bayoumy K, Gaber M, Elshafeey A, Mhaimeed O, Dineen EH, Marvel FA, et al. Smart wearable
513 devices in cardiovascular care: where we are and how to move forward. *Nat Rev Cardiol*
514 2021;18:581–599. doi:10.1038/s41569-021-00522-7.
- 515 42. Garcia R, Warming PE, Narayanan K, Defaye P, Guedon-Moreau L, Blangy H, et al. Dynamic
516 changes in nocturnal heart rate predict short-term cardiovascular events in patients using the
517 wearable cardioverter-defibrillator: from the WEARIT-France cohort study. *EP Europace*
518 2023;25:euad062. doi:10.1093/europace/euad062.
- 519 43. Marijon E, Narayanan K, Smith K, Barra S, Basso C, Blom MT, et al. The Lancet Commission to
520 reduce the global burden of sudden cardiac death: a call for multidisciplinary action. *The Lancet*
521 2023;402:883–936. doi:10.1016/S0140-6736(23)00875-9.
- 522 44. Marijon E, Garcia R, Narayanan K, Karam N, Jouven X. Fighting against sudden cardiac death:
523 need for a paradigm shift—Adding near-term prevention and pre-emptive action to long-term
524 prevention. *European Heart Journal* 2022;43:1457–1464. doi:10.1093/eurheartj/ehab903.

Tables and figures

Legends

Table 1: Characteristics of all sudden cardiac death (SCD) cases, stratified by time period.

Table 2: Incidence rates and temporal trends of sudden cardiac death (SCD) in the young aged 1–35

Figure 1: Temporal trends in sudden cardiac death (SCD) incidence from 2000–2019

Figure 2: Temporal trends in sudden cardiac death (SCD) incidence, by sex (panel A) and witnessed status (panel B).

Figure 3: Temporal trends in bystander cardiopulmonary resuscitation (CPR) (Panel A) and cardiac arrest survival (panel B) in the young aged 1–35.

Figure 4: Temporal trends in implantable cardioverter defibrillator implantation in the young aged 1–35. Panel A: Implantations of primary and secondary preventive ICD. Panel B: Trends in the proportion of secondary preventive ICD of all ICDs implanted.

542 Table 1: Characteristics of all sudden cardiac death (SCD) cases, stratified by time period.

Characteristic ¹	Overall N = 1 057	2000-2003 N = 277	2004-2007 N = 247	2008-2011 N = 203	2012-2015 N = 169	2016-2019 N = 161	Estimated 20-year RR	95%CI for RR
Male sex	733 (69%)	173 (62%)	183 (74%)	144 (71%)	113 (67%)	120 (75%)	1.13	0.99–1.29
Age	29 (22–33)	29 (23–33)	29 (22–33)	29 (22–34)	28 (22–33)	29 (22–32)	-0.18 yr	-1.90–1.54
<u>Comorbidity</u>								
Any of the below	414 (39%)	75 (27%)	92 (37%)	87 (43%)	89 (53%)	71 (44%)	1.62	1.28–2.02
HT	51 (5%)	14 (5%)	12 (5%)	9 (4%)	5 (3%)	11 (7%)	1.12	0.44–2.82
CVD	167 (16%)	44 (16%)	45 (18%)	29 (14)	24 (14%)	25 (16%)	0.86	0.53–1.39
IHD	22 (2%)	7 (3%)	8 (3%)	<= 3	<= 3	5 (3%)	0.63	0.14–2.66
Prev. MI	14 (1%)	4 (1%)	5 (2%)	<= 3	<= 3	5 (3%)	1.34	0.21–8.04
Prev. CA	9 (1%)	<= 3	4 (2%)	<= 3	<= 3	<= 3	0.44	0.033–4.32
AF	19 (2%)	6 (2%)	<= 3	<= 3	5 (3%)	<= 3	0.98	0.20–4.55
CM	32 (3%)	11 (4%)	8 (3%)	7 (3%)	<= 3	<= 3	0.41	0.11–1.37
Conduct. disease	44 (4%)	10 (4%)	11 (5%)	6 (3%)	9 (5%)	8 (5%)	1.33	0.48–3.58
Congenital HD	66 (6%)	17 (6%)	17 (7%)	13 (6%)	11 (7%)	8 (5%)	0.80	0.35–1.81
ICD	8 (1%)	<= 3	<= 3	<= 3	<= 3	4 (3%)	39.50	2.91–1030
Epilepsy	143 (14%)	15 (5%)	23 (9%)	36 (18%)	38 (22%)	31 (19%)	4.48	2.69–7.50
Psychiatric disease	193 (18%)	25 (9%)	37 (15%)	42 (20%)	53 (31%)	36 (22%)	2.70	2.01–4.69
Diabetes	44 (4%)	11 (4%)	15 (6%)	9 (4%)	4 (2Q%)	5 (3%)	0.64	0.22–1.75
<u>Death-related circumstances</u>								
Unwitnessed SCD	577 (59%)	120 (47%)	112 (51%)	112 (58%)	123 (74%)	110 (73%)	1.79	1.51–2.12
Dead in sleep	322 (36%)	78 (33%)	75 (36%)	60 (35%)	47 (35%)	62 (44%)	1.32	0.97–1.77
Sports related	58 (5.6%)	16 (5.8%)	15 (6.1%)	14 (6.9%)	6 (3.6%)	7 (4.7%)	0.80	0.33–1.92
Autopsy performed	707 (67%)	182 (66%)	166 (67%)	148 (73%)	107 (63%)	104 (65%)	0.96	0.83–1.12

¹Data are n (%) and median (Q1-Q3).

AF: Atrial fibrillation, CA: Cardiac arrest, CM: Cardiomyopathy, CVD: Cardiovascular disease, HT: Hypertension, ICD: Implantable cardioverter defibrillator, IHD: Ischemic heart disease, MI: Myocardial infarction, RR = relative risk, SCD: Sudden cardiac death

	SCD cases	Person-years	Crude incidence estimates				Adjusted annual changes	
			Crude IR	IR 95%CI	IRR	IRR 95%CI	PCA (%)	PCA 95%CI
All SCD	1 057	47.5 million	2.2	2.1-2.4	-	-	-3.31	-4.2 to -2.42
By groups								
Time period								
2000-2003	277	9.6 million	2.89	2.56-3.24	-	-	-	-
2004-2007	247	9.4 million	2.6	2.3-3.0	0.91	0.77-1.1	-	-
2008-2011	203	9.4 million	2.2	1.9-2.5	0.75	0.62-0.89	-	-
2012-2015	169	9.4 million	1.8	1.5-2.1	0.62	0.51-0.75	-	-
2016-2019	161	9.7 million	1.67	1.42-1.94	0.58	0.47-0.7	-	-
Sex								
Female	324	23.3 million	1.4	1.2-1.5	-	-	-4.66	-6.17 to -3.14
Male	733	24.2 million	3.0	2.8-3.3	2.2	1.9-2.5	-2.73	-3.95 to -1.50
Age								
1-18	175	23.8 million	0.74	0.63-0.85	-	-	-4.7	-7.5 to -1.9
19-35	882	23.7 million	3.70	3.50-4.00	5.1	4.3-6.0	-2.8	-3.9 to -1.8
Witnessed status								
Witnessed	406	47.5 million	0.85		-	-	-7.03	-5.46 to -2.71
Unwitnessed	651	47.5 million	1.37		1.6	-	-0.09	-1.48 to 1.31
CI: Confidence interval, IR: Incidence rates, IRR: Incidence rate ratio, PCA: Percentage change annualized, SCD: Sudden cardiac death								

Figure 1: Temporal trends in SCD incidence from 2000–2019




Figure 2: Temporal trends in SCD incidence, by sex and witnessed status




Figure 3: Temporal trends in OHCA survival and bystander CPR in the young aged 1–35





Figure 4: Temporal trends in ICD implantations in the young aged 1–35



562 Suppl. Table 1: Definitions of comorbidities and ICD-codes used to define
563 diseases

564 Hypertension	<i>Prescription claims of two of the following drugs w/i 180 days:</i> ACE/ARB, Beta blockers, Loop diuretics, MRA, ARNI, Thiazides
Cardiovascular disease	ICD-10: DI110, DI130, DI20-51, DQ20-26 ICD-8: 410-414, 425, 427, 428, 746, 747
Ischemic heart disease	ICD-10: DI20-25 ICD-8: 410-414
Prev. MI	ICD-10: DI21-23, DI252, ICD-8: 410-411
Prev. CA	DI46
AF	ICD-10: DI48 ICD-8: 42793, 42794
Cardiomyopathy	ICD-10: DI42-DI43 ICD-8: 425
Conduction diseases	ICD10: DI44-45, DI47, DI49
Congenital HD	ICD-10: DQ20-26 ICD-8: 746, 747
ICD	ICD-10: DZ950A, DZ950C, DZ950D, UFYA31", ZZ4051, BFCB, KFPG
Epilepsy	ICD-10: DG40-41 ICD-8: 345
Psychiatric disease	ICD10: DF101-109, DF111-119, DF121-129, DF131-139, DF141-149, DF151-159, DF161, DF171-179, DF181-189, DF191-199, DF20-99 ICD8: 29,300-301, 305-315 <u>OR</u> <i>Prescription claims of any antipsychotic drug w/i 180 days</i>
Diabetes	ICD-10: DE10-14 ICD-8: 249, 250 <u>OR</u> <i>Prescription claims of one of the following drugs w/i 180 days:</i> Insulin, Metformin, Biguanid, Sulfonylurea, Sulfomid, Thiazolidinidion, DPP4-inhibitor, GLP1-agonist, SGLT2-inhib

565 Suppl. Table 2: Characteristics of the general population, stratified by year

	Overall	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Population	47 512 622	2 414 649	2 403 520	2 392 209	2 375 476	2 360 593	2 351 574	2 347 356	2 347 663	2 350 387	2 354 962
Male sex	24 212 851 (51%)	1 233 010 (51%)	1 226 108 (51%)	1 219 309 (51%)	1 209 652 (51%)	1 201 661 (51%)	1 196 358 (51%)	1 193 712 (51%)	1 193 723 (51%)	1 195 151 (51%)	1 197 905 (51%)
Age	18 (10–27)	20 (9–28)	19 (9–28)	19 (9–28)	19 (9–28)	18 (9–28)	18 (9–28)	18 (9–28)	18 (9–28)	18 (9–27)	18 (9–27)
<u>Comorbidity</u>											
Any	2 661 419 (6%)	98 914 (4%)	100 907 (4%)	103 599 (4%)	105 834 (5%)	108 175 (5%)	110 685 (5%)	113 408 (5%)	118 171 (5%)	122 296 (5%)	126 577 (5%)
Hypertension	57 073 (0.1%)	2 156 (<0.1%)	2 258 (<0.1%)	2 405 (0.1%)	2 485 (0.1%)	2 768 (0.1%)	3 096 (0.1%)	3 195 (0.1%)	3 492 (0.1%)	3 706 (0.2%)	3 811 (0.2%)
CVD	542 145 (1.1%)	20 212 (0.8%)	20 979 (0.9%)	21 923 (0.9%)	22 526 (0.9%)	23 011 (1.0%)	23 425 (1.0%)	23 806 (1.0%)	24 481 (1.0%)	25 152 (1.1%)	25 993 (1.1%)
IHD	34 359 (<0.1%)	1 393 (<0.1%)	1 487 (<0.1%)	1 633 (<0.1%)	1 670 (<0.1%)	1 750 (<0.1%)	1 829 (<0.1%)	1 822 (<0.1%)	1 832 (<0.1%)	1 809 (<0.1%)	1 800 (<0.1%)
Prev. MI	8 464 (<0.1%)	436 (<0.1%)	435 (<0.1%)	459 (<0.1%)	443 (<0.1%)	468 (<0.1%)	468 (<0.1%)	453 (<0.1%)	458 (<0.1%)	457 (<0.1%)	456 (<0.1%)
Prev. CA	3 248 (<0.1%)	59 (<0.1%)	58 (<0.1%)	60 (<0.1%)	62 (<0.1%)	74 (<0.1%)	79 (<0.1%)	83 (<0.1%)	101 (<0.1%)	109 (<0.1%)	115 (<0.1%)
AF	24 152 (<0.1%)	801 (<0.1%)	891 (<0.1%)	971 (<0.1%)	1 058 (<0.1%)	1 093 (<0.1%)	1 117 (<0.1%)	1 156 (<0.1%)	1 210 (<0.1%)	1 239 (<0.1%)	1 269 (<0.1%)
CM	15 285 (<0.1%)	464 (<0.1%)	516 (<0.1%)	560 (<0.1%)	599 (<0.1%)	629 (<0.1%)	667 (<0.1%)	687 (<0.1%)	708 (<0.1%)	741 (<0.1%)	746 (<0.1%)
Cond. def.	157 218 (0.3%)	4 251 (0.2%)	4 772 (0.2%)	5 255 (0.2%)	5 727 (0.2%)	6 181 (0.3%)	6 473 (0.3%)	6 746 (0.3%)	7 034 (0.3%)	7 338 (0.3%)	7 620 (0.3%)
Congenital	263 384 (0.6%)	11 102 (0.5%)	11 138 (0.5%)	11 331 (0.5%)	11 373 (0.5%)	11 308 (0.5%)	11 348 (0.5%)	11 348 (0.5%)	11 664 (0.5%)	11 995 (0.5%)	12 553 (0.5%)
ICD	5 234 (<0.1%)	34 (<0.1%)	47 (<0.1%)	62 (<0.1%)	74 (<0.1%)	105 (<0.1%)	126 (<0.1%)	137 (<0.1%)	152 (<0.1%)	182 (<0.1%)	203 (<0.1%)
Epilepsy	422 613 (0.9%)	22 394 (0.9%)	22 498 (0.9%)	22 483 (0.9%)	22 306 (0.9%)	21 807 (0.9%)	21 622 (0.9%)	21 590 (0.9%)	21 528 (0.9%)	21 335 (0.9%)	21 206 (0.9%)
Psychiatric	1 291 418 (2.7%)	35 763 (1.5%)	37 237 (1.5%)	39 112 (1.6%)	41 240 (1.7%)	43 576 (1.8%)	45 845 (1.9%)	47 594 (2.0%)	51 258 (2.2%)	54 983 (2.3%)	58 932 (2.5%)
Diabetes	262 910 (0.5%)	9 311 (0.5%)	9 419 (0.5%)	9 552 (0.5%)	9 761 (0.5%)	10 204 (0.5%)	10 917 (0.5%)	12 078 (0.5%)	12 938 (0.5%)	13 575 (0.5%)	13 876 (0.5%)
Deaths	15 189	1 080	1 048	1 088	979	952	852	828	843	848	789
SCD	1 057	71	69	66	71	75	67	41	64	51	57

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Est. 20-year RR	95% CI RR
Population	2 356 252	2 357 053	2 355 283	2 356 580	2 362 855	2 369 955	2 392 219	2 409 309	2 425 936	2 428 791	-	-
Male sex	1 198 188 (51%)	1 198 897 (51%)	1 198 593 (51%)	1 199 630 (51%)	1 204 002 (51%)	1 209 250 (51%)	1 222 689 (51%)	1 232 163 (51%)	1 240 838 (51%)	1 242 012 (51%)	1.003	1.003- 1.004
Age	18 (9–27)	18 (9–27)	18 (10–27)	18 (10–26)	18 (10–26)	19 (10–26)	19 (10–27)	19 (10–27)	19 (10–27)	19 (10–27)		
<u>Comorbidity</u>												
Any	131 658 (5.5%)	137 752 (6%)	143 513 (6%)	149 705 (6.5%)	155 353 (6.5%)	160 769 (7%)	166 271 (7%)	171 486 (7%)	176 917 (7.5%)	-	1.87	1.87- 1.88
Hypertensio	3 539 (0.2%)	3 536 (0.2%)	3 356 (0.1%)	3 252 (0.1%)	3 015 (0.1%)	2 763 (0.1%)	2 805 (0.1%)	2 732 (0.1%)	2 703 (0.1%)	-	0.86	0.84- 0.89
CVD	26 795 (1.1%)	27 892 (1.2%)	28 911 (1.2%)	29 919 (1.3%)	30 760 (1.3%)	31 783 (1.3%)	33 053 (1.4%)	34 132 (1.4%)	35 131 (1.4%)	-	1.75	1.73- 1.76
IHD	1 747 (<0.1%)	1 887 (<0.1%)	1 876 (<0.1%)	1 850 (<0.1%)	1 799 (<0.1%)	1 811 (<0.1%)	1 771 (<0.1%)	1 683 (<0.1%)	1 591 (<0.1%)	-	1.02	0.98- 1.06
Prev. MI	430 (<0.1%)	438 (<0.1%)	427 (<0.1%)	409 (<0.1%)	378 (<0.1%)	377 (<0.1%)	391 (<0.1%)	386 (<0.1%)	389 (<0.1%)	-	0.77	0.71- 0.82
Prev. CA	135 (<0.1%)	147 (<0.1%)	180 (<0.1%)	214 (<0.1%)	254 (<0.1%)	274 (<0.1%)	292 (<0.1%)	311 (<0.1%)	329 (<0.1%)	-	8.05	7.06- 9.19
AF	1 291 (<0.1%)	1 288 (<0.1%)	1 307 (<0.1%)	1 359 (<0.1%)	1 356 (<0.1%)	1 400 (<0.1%)	1 389 (<0.1%)	1 379 (<0.1%)	1 387 (<0.1%)	-	1.50	1.44- 1.57
CM	776 (<0.1%)	815 (<0.1%)	843 (<0.1%)	894 (<0.1%)	935 (<0.1%)	934 (<0.1%)	939 (<0.1%)	968 (<0.1%)	987 (<0.1%)	-	1.95	1.85- 2.06
Cond. def.	7 922 (0.3%)	8 232 (0.3%)	8 665 (0.4%)	9 117 (0.4%)	9 498 (0.4%)	9 899 (0.4%)	10 395 (0.4%)	10 832 (0.4%)	11 124 (0.5%)	-	2.39	2.35- 2.44
Congenital	13 036 (0.6%)	13 568 (0.6%)	14 012 (0.6%)	14 358 (0.6%)	14 688 (0.6%)	15 056 (0.6%)	15 532 (0.6%)	15 982 (0.7%)	16 543 (0.7%)	-	1.58	1.55- 1.60
ICD	236 (<0.1%)	268 (<0.1%)	293 (<0.1%)	336 (<0.1%)	398 (<0.1%)	439 (<0.1%)	476 (<0.1%)	551 (<0.1%)	571 (<0.1%)	-	11.03	9.92- 12.27
Epilepsy	20 812 (0.9%)	20 656 (0.9%)	20 656 (0.9%)	20 697 (0.9%)	20 725 (0.9%)	20 541 (0.9%)	20 503 (0.9%)	20 304 (0.8%)	20 307 (0.8%)	-	0.86	0.85- 0.87
Psychiatric	64 161 (2.7%)	69 324 (2.9%)	74 441 (3.2%)	79 703 (3.4%)	84 552 (3.6%)	88 781 (3.7%)	92 548 (3.9%)	95 602 (4.0%)	98 548 (4.1%)	-	3.06	3.04- 3.08
Diabetes	14 330 (0.5%)	14 707 (0.5%)	14 935 (0.5%)	15 105 (0.5%)	15 251 (0.5%)	15 148 (0.5%)	15 261 (0.5%)	15 692 (0.5%)	16 150 (0.5%)	-	1.77	1.75- 1.79
Deaths	675	685	584	564	590	538	605	560	571	507	-	-
SCD	47	48	44	43	43	39	34	42	40	45	-	-

567 Suppl. Table 3: Characteristics of out-of-hospital cardiac arrest victims, stratified by sex and time group

		Overall	2001-2003	2004-2007	2008-2011	2012-2015	2016-2019	Est. 19-year relative risk	95%CI RR
Female	Number	757	86	142	151	151	227		
	Age	24 (17-31)	25 (19-32)	25 (16-32)	26 (20-32)	23 (16-30)	24 (17-30)	-0.75 yr	-3.22 – 1.72
	Public location	190 (33%)	4 (44%)	16 (29%)	42 (32%)	49 (33%)	79 (35%)	1.10	0.66 – 1.91
	Shock. rhythm	125 (18%)	15 (19%)	14 (11%)	25 (18%)	26 (18%)	45 (21%)	1.57	0.90 – 2.78
	Bystander witnessed	264 (35%)	22 (26%)	46 (32%)	48 (32%)	60 (40%)	88 (39%)	1.49	1.07 – 2.10
	Bystander CPR	453 (60%)	23 (27%)	52 (37%)	80 (53%)	111 (74%)	187 (82%)		
	Bystander AED	26 (3.4%)	<=3	<= 3	<= 3	3 (2.0%)	20 (8.9%)	41.2	7.19 – 334.00
	30-day survival	164 (22%)	3 (3.5%)	18 (13%)	28 (19%)	43 (28%)	72 (33%)	6.07	3.61 – 10.40
Male	Number	1 805	246	330	376	324	529		
	Age	26 (19-31)	27 (21-32)	27 (19-32)	25 (19-31)	25 (19-31)	24 (19-31)	-1.56yr	-3.02 to -0.10
	Public location	592 (44%)	11 (65%)	62 (47%)	153 (45%)	131 (41%)	235 (45%)	0.91	0.70 – 1.20
	Shock. rhythm	314 (19%)	50 (22%)	48 (16%)	63 (19%)	59 (19%)	94 (19%)	1.02	0.73 – 1.43
	Bystander witnessed	621 (35%)	71 (29%)	99 (30%)	128 (34%)	117 (36%)	206 (39%)	1.46	1.17 – 1.81
	Bystander CPR	1 016 (56%)	75 (30%)	120 (36%)	198 (53%)	213 (66%)	410 (78%)		
	Bystander AED	56 (3.1%)	<= 5	<= 5	5 (1.3%)	8 (2.5%)	37 (7.2%)	15.00	5.26 – 47.3
	30-day survival	282 (16%)	10 (4.1%)	31 (9.4%)	44 (12%)	61 (19%)	136 (26%)	6.11	4.09 – 19.25

¹Median (IQR); n (%)

AED: automated external defibrillators, CPR: cardiopulmonary resuscitation